What’s to be done about skyrocketing health care costs and the growing number of New Yorkers without health insurance? Two new op-ed pieces by Manhattan Institute senior fellows suggest an answer to that question.

In today’s New York Post, Prof. Regina Herzlinger of Harvard Business School challenges the view that the solution lies in more government intervention. As things now stand, she notes,

…government-controlled health insurance is so expensive that nearly 40 percent of New York’s non-elderly uninsured are middle-class families, with annual incomes at least double the poverty level. The uninsured rate is well above the national average in the state’s wealthiest region — New York City and its suburbs.Why can poor people afford to buy cars while middle-class people can’t afford to buy health insurance?

Her answer: the auto industry is consumer-driven, responding to the same market forces that could shape a better, less expensive forms of health insurance.

E.J. McMahon reaches a similar conclusion his Syracuse Post Standard piece. Government, he points out, is a big part of the problem.

For example, the tax burden on health insurance sold in New York has been steadily increasing … In 2005-06, the state will collect roughly $2.1 billion in taxes and assessments from private health plans. In fact, private health insurance plans now rank as the Empire State’s third largest source of non-federal revenue, behind the personal income and sales and use taxes. It’s axiomatic, of course, that when you tax some thing more, you get less of it — at a higher price.A second big problem is the state’s insistence on requiring all health insurance policies to cover a large array of treatments, conditions and providers. New York imposes 43 health insurance mandates — among the most of any state and well above the national average.

The issue will be explored in more detail by Prof. Herzlinger and other speakers at the Empire Center’s health policy forum at the State Capitol in Albany on Thursday, May 26.

Tags:

About the Author

Tim Hoefer

Tim Hoefer is president & CEO of the Empire Center for Public Policy.

Read more by Tim Hoefer

You may also like

The Attorney General’s MFCU SNAFU

Attorney General Letitia James' latest fight with the Trump administration focuses on New York's Medicaid Fraud Control Unit, a federally funded agency housed in James' office. On T Read More

Healthcare Revelations in the Enacted Budget Financial Plan

The state financial plan published on June 10 disclosed key information about healthcare revenue and spending that lawmakers had not made public when approving the annual budget two weeks before. Read More

Federal Suit Traces Medicaid Fraud to the Top of NYS Government

The Trump administration's latest salvo against Medicaid fraud takes aim at a different kind of target – two high-ranking New York officials along with a major state contractor. A Read More

Healthcare Highlights in the New State Budget

Governor Hochul's focus on affordability seems to have skipped over the healthcare portions of the new state budget. The deal finalized May 27 Read More

Lawmakers Consider Hiking Fees for Filling Prescriptions

UPDATE: The proposal discussed below passed the Assembly Friday evening by an unofficial vote of 133-0. Having previously been approved by the Senate, the bill will head to Governor Hochul's desk for her signature or ve Read More

Budget Deal Reportedly Earmarks $100M for 1199 and Extends MCO Tax

As Governor Hochul and legislative leaders rush to finalize the overdue state budget, outlines of some healthcare-related deals have begun to emerge from the closed-door negotiations. Read More

Albany Wavers on Shutting Down a Medicaid Racket

As Washington threatens to crack down on fraud and abuse in New York's Medicaid program, state legislators are doing their best to demonstrate why federal intervention is needed. A Read More

Getting to the Bottom of the 340B Drug Discount Boondoggle

Some of New York's largest and most prosperous hospitals are reporting rapidly growing amounts of revenue from pharmacy sales – most of it apparently flowing from a controversial drug discount program known as 340B. Read More